Phenotypic Drug Screening for Dysferlinopathy Using Patient-Derived Induced Pluripotent Stem Cells

Yuko Kokubu(BrightPath Biotherapeutics (Japan)), Hidetoshi Sakurai(Kyoto University)

Stem Cells Translational Medicine

June 28, 2019

10.1002/sctm.18-0280

Cited by 35

Related Papers

A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs

|Cell Reports Medicine|2021|36

Single-cell RNA-seq reveals heterogeneity in hiPSC-derived muscle progenitors and E2F family as a key regulator of proliferation

|Life Science Alliance|2022|12

Orai1–STIM1 Regulates Increased Ca2+ Mobilization, Leading to Contractile Duchenne Muscular Dystrophy Phenotypes in Patient-Derived Induced Pluripotent Stem Cells

|Biomedicines|2021|7

Uniform transgene activation in Tet-On systems depends on sustained rtTA expression

|iScience|2023|5

Distinct muscle regenerative capacity of human induced pluripotent stem cell-derived mesenchymal stromal cells in Ullrich congenital muscular dystrophy model mice

|Stem Cell Research & Therapy|2024|5